CAJ | 학술논문

随着大量与人类疾病和药物治疗相关的单核苷酸多态性（ Single-nucleotide polymorphism ， SNP）的发现，出现了多种SNP分型检测的方法和技术。然而，大多数方法由于受限于检测灵敏度低或对检测设备和实验条件要求较高，不适宜于在一般实验条件下进行常规临床检测。通过建立一种基于连接酶-ELISA的SNP快速分型新方法，以非小细胞肺癌个体化治疗中，酪氨酸激酶抑制剂药物的生物标记基因-表皮生长因子受体基因（ EGFR ）为检测对象，对EGFR， c.2573T＞G（L858R）， EGFR， c.2582T＞A（L861Q）和EGFR， c.2155 G＞T（G719C）3个SNP位点进行了突变检测。经过18～28个循环的PCR扩增，能够通过琼脂糖凝胶电泳和ELISA反应，根据电泳条带的有无和ELISA显色值清晰判断检测位点的基因型，并且能够从混合等位基因样本中检测出5％的突变型等位基因。结果表明，方法具有较高的特异性和灵敏度，适合于在常规实验条件下从不均一的样本中进行突变等位基因的检测。
수착대량여인류질병화약물치료상관적단핵감산다태성（ Single-nucleotide polymorphism ， SNP）적발현，출현료다충SNP분형검측적방법화기술。연이，대다수방법유우수한우검측령민도저혹대검측설비화실험조건요구교고，불괄의우재일반실험조건하진행상규림상검측。통과건립일충기우련접매-ELISA적SNP쾌속분형신방법，이비소세포폐암개체화치료중，락안산격매억제제약물적생물표기기인-표피생장인자수체기인（ EGFR ）위검측대상，대EGFR， c.2573T＞G（L858R）， EGFR， c.2582T＞A（L861Q）화EGFR， c.2155 G＞T（G719C）3개SNP위점진행료돌변검측。경과18～28개순배적PCR확증，능구통과경지당응효전영화ELISA반응，근거전영조대적유무화ELISA현색치청석판단검측위점적기인형，병차능구종혼합등위기인양본중검측출5％적돌변형등위기인。결과표명，방법구유교고적특이성화령민도，괄합우재상규실험조건하종불균일적양본중진행돌변등위기인적검측。
With the discovery of large number of single nucleotide polymorphism ( SNP) related to human diseases and drug therapy , a large number of approaches for parallel genotyping have been developed .However, these methods require either complicated laboratory procedures or expensive instrumentation .None of these procedures is readily performed in clinical laboratories .In this study, we devel-oped a flexible genotyping method that aims to be inexpensive , accurate, and adapted to routine analysis .The process was called ligase reaction with enzyme-linked immunosorbent assay .This assay was successfully applied to the detection of important SNPs of the EGFR gene at loci of c.2573T>G (L858R), c.2582T>A (L861Q), and c.2155 G>T (G719C).This assay exhibited an excellent speci-ficity, with a sensitivity as low as 5%.With agarose gel electrophoresis and ELISA detection , the genotypes were identified by the present of bands and the values of ELISA detection after 18-28 PCR cycles .In conclusion , the developed technology enables accurate identification of sequence variants in a simple and cost-effective manner from heterogeneous samples unambiguously .